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HIV is a pandemic infection with cases notified in almost all countries. The reported prevalence 
of symptoms in the head and neck is about 80%; otolaryngologists may be the first physician to see 
such patients. Oral manifestations are the most common, followed by neck and sinus manifestations. 
Otolaryngologic symptoms may be important signs of antiretroviral therapy failure. Symptoms are 
present in acute infections and advanced cases.
Objective: To describe new approaches in the past five years for the treatment of the most frequent 
otolaryngologic manifestations in HIV patients.
Methods: Systematic reviews and case series published in English and Portuguese from January 
2002 to October 2007 including the most common otolaryngology manifestations were selected. 
Conclusion: Otolaryngologic manifestations are common and ENT specialists must be prepared to 
identify such cases. 
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INTRODUCTION
Retrospective studies suggest that the prevalence 
of head and neck symptoms is about 80%. Oral ma-
nifestations are the most frequent, followed by neck, 
sinus, and otological findings.1 These symptoms may 
present during acute infections or advanced stages of 
disease. Oral lesions may be relevant clinical markers 
of antiretroviral treatment failure.2
The purpose of this review of the literature was to 
describe current advances in the treatment of the main 
otorhinolaryngological manifestations in HIV-positive 
patients; the survey comprised papers published from 
2002 to 2007.
MATERIALS AND METHODS
The review was made in Pubmed of the most 
common published otorhinolaryngological findings. 
Case series and systematic reviews in English and Por-
tuguese, published from January 2002 to October 2007 
were selected.
The main otorhinolaryngological manifestations 
and their treatment were classified according to disease 
site and prevalence. Oral manifestations: oral candidia-
sis; pilous leukoplakia; recurrent aphthous stomatitis; 
neoplasms (Kaposi’s sarcoma and lymphomas); con-
ditions caused by herpes simplex, herpes zoster, and 
the human papillomavirus (HPV); periodontal disease; 
and oral tuberculosis. Nasosinusal manifestations: acute 
and chronic rhinosinusitis; allergic rhinitis; neoplasms 
(Kaposi’s sarcoma and lymphomas). Manifestations in 
the neck: enlarged lymph nodes; salivary gland invol-
vement. Otological manifestations: acute and chronic 
otitis media; secretory otitis media; external otitis; polyps 
in the outer ear canal; neoplasm (Kaposi’s sarcoma); 
sensorineural hearing loss; peripheral facial palsy.
DISCUSSION
Oral lesions (Table 1)
1. Candidiasis: this is the most common disease 
in the mouth of HIV/AIDS patients. Its estimated pre-
valence in Latin America is about 40% of oral lesions 
(Ranganathan et al.3). The causative agent is Candida 
albicans, and this disease is frequently found at the 
beginning of HIV infection in previously asymptoma-
tic patients; it is also present in 90% AIDS patients. A 
well established factor for this infection is a decrease 
in circulating CD4+ T lymphocytes.2,4-6 Candidiasis is 
considered as a marker of failure of antiretroviral the-
rapy with or without protease inhibitors.2,7 The three 
most common forms of candidiasis in the mouth of HIV 
infected patients are the pseudomembranous form, the 
erythematous form, and angular cheilitis.5
Angular cheilitis may occur as erythematous 
lesions or splits in the corners of the mouth. Erythema-
tous candidiasis presents as atrophic lesions or reddish 
maculae on the palate and dorsum of the tongue; it 
may be present in other areas of the tongue. Acute 
pseudomembranous candidiasis is the most common 
form; it presents as easily removable white or yellowish 
plaques on the mucosa, which is hyperemic and may 
bleed.5,8 These two forms may occur simultaneously.8 
Lesions may extend throughout the mouth in severely 
immunodeficient patients.5 The diagnosis is based on 
clinical findings.8
2. Pilous leukoplakia: this is a rough-surfaced 
flat whitish lesion on the lateral aspect of the tongue. 
The cause is the Epstein-Barr virus, and it is generally 
asymptomatic. It is also a reliable marker of HIV infec-
tion and its progression, and of failure of antiretroviral 
therapy.2,6,7 It is also related (like oral candidiasis) with 
decreased levels of circulating CD4 cells in HIV sero-
positive patients.6,9 It should be noted that this is not an 
exclusive disease of HIV seropositive patients; it may 
occur in other immune suppressive states or even in 
subjects with intact immune systems.10
Therapy aims to reduce the size of this lesion 
rather than its eradication, and is indicated when pi-
lous leukoplakia interferes with feeding or for esthetic 
reasons; there are no studies indicating a treatment of 
choice.11
3. Recurrent aphthous stomatitis (RAS): this di-
sease features painful ulcers (aphthae) of varying size 
and duration located typically on the non-keratinized 
oral mucosa. The cause is not clear in spite of much 
research.12 There are three main forms: minor, major, 
and herpetiform. These ulcers may vary by number, 
size, or duration, although it is not always possible to 
differentiate them clearly.12,13
Major ulcers are directly associated with the im-
mune status of seropositive patients. Miziara et al., in a 
study of 94 seropositive AIDS patients with RAS, noted 
that major ulcers were associated with lower CD4+ e 
CD8+ counts and increased inversion of the CD4+/CD8+ 
ratio compared to patients with minor and herpetiform 
ulcers. Furthermore, the number of patients with major 
ulcers and absolute CD4+ cell counts below 60 was 
higher compared to that of patients with herpetiform 
and minor ulcers.13
Thalidomide is the most effective treatment; the 
benefit of this drug should be weighed against the risk 
of adverse effects and teratogenicity.14 A multicentric 
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study by Jacobson et al. (2001) compared low intermit-
tent doses of thalidomide (100 mg 3 times a week) with 
placebo for the prevention of mouth and esophageal 
ulcers in patients successfully treated with thalidomide 
in the past, and showed that this drug was not effective 
for this specific purpose.11,15
4. Kaposi’s sarcoma (SC): this disease is clinically 
similar to other vascular lesions such as hemangioma, 
ecchymosis, or accumulated melanic pigment with 
spots, plaques or nodules; it may become symptomatic 
if there is secondary infection or trauma, when it may 
cause pain and speech and swallowing disorders.5 Its 
incidence has fallen dramatically with the advent of 
antiretroviral therapy (ART).16
The main sites in the mouth are the palate and the 
gingival, but it may be found throughout the mouth.8 It 
may be associated with human herpes virus (HPV) 88,10 
and 4.10 The diagnosis is made with a biopsy; treatment 
is radiotherapy, local chemotherapy (vinblastine or 
sodium sulphate tetradecil) and surgery.5,10,11 Systemic 
chemotherapy is an option in advanced cases.8
5. Herpes simplex: this disease involves reacti-
vation of a latent virus in the trigeminal ganglion; the 
main form in seropositive patients is related with a fall 
in circulating CD4 cells and increased viral load. The 
typical lesions are vesicles on the lips or mouth that 
coalesce to form painful irregular ulcers with whitish 
borders.5 The CD4 cell count must be taken into account 
in the treatment of herpes simplex. If the count is over 
200, topical treatment is used for perioral herpes sim-
plex until the lesions clear; if the count is below 200, 
or if there are extensive lesions, or if the patient did not 
respond to topical treatment, a systemic antiviral agent 
such as acyclovir is warranted. Still more severe cases 
require endovenous medication; intravenous foscarnet 
may be used in patients with acyclovir-resistant strains.11
Table 1. Treatment of the main oral manifestations of the HIV patient
Oral lesions 1st choice of therapy Other treatment possibilities
Oral candidiasis
Angular cheilitis  - nystatin cream 4x/day/14 
days.
Angular cheilitis - clotrimazole cream 4x/
day/14 days.
Other forms of candidiasis -
CD4>200: nistatina solução 4 - 6ml 4x/dia /7-
14 dias. Other forms of candidiasis -
CD4>200: itraconazole 200 mg solution 
1x/day /7-14 days.CD4<200: fluconazole 100 mg (VO) 1x/day/7-
14 days. Severe cases: amphothericin B  (EV)0.3 
mg/kg 1x/day.
Pillous leukoplakia
Topical podophyllin 0.25% - once
Topical retinoids (vitamin A 0.1%) - 2x/day
Acyclovir VO 800 mg 6/6h for 20 days
Herpes zoster Thalidomide 200 mg/day.
Periodontal disease
CD4>200: topical acyclovir until lesions 
disappear.
Acyclovir-resistant patients - foscarnet: 
continuous infusion for 24 hours (20 mg/kg 
weight) or intermittent infusion every 8 hours 
of 60 mg/ml doses in patients with normal 
kidney function.
CD4<200 / extensive lesions not responding 
to topical therapy: acyclovir 400 mg (VO) 5x/day. 
Severe cases: acyclovir EV.
Herpes zooster
Acyclovir 800mg (VO)5x/dia. Famcyclovir
Cases of viral dissemination - acyclovir (EV) 
10 mg/kg  8/8h.
Valacyclovir
Post-herpetic neuralgia - amitriptyline up to 
100 mg/day.
Periodontal disease
Odontologic debridement
Chlorhexidine 0.12% - mouth wash 2x/day 
for 14 days.
Necrotizing ulcerative periodontit is - 
Metronidazole 500 mg 2x/day for 7 to 10 days 
VO: oral route; EV: endovenous route
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6. Herpes zoster: the varicella-zoster virus is asso-
ciated with chronic lesions, frequent relapses, and even 
death if the virus disseminates in immunosuppressed 
patients. The trigeminal nerve – particularly its first 
division – is involved in about 15% to 20% of herpes 
zoster cases, which leads to ocular and scalp lesions. 
The mouth and face become involved when the virus 
reaches the second and third divisions – there may be 
blisters, vesicles, and unilateral pain. The main sites in 
the mouth are the palate, the tongue, and the lips.11
Prompt treatment is required because of post-
herpetic neuralgia, which has a high rate in seropositive 
patients.11 Acyclovir is the drug of choice; it is used 
intravenously if the virus has disseminated. Famciclo-
vir and valacyclovir are other choices.  Post-herpetic 
neuralgia may be treated with tricyclic antidepressants 
and intralesional corticosteroids.11
7. Lesions caused by the human papillomavirus 
(HPV): as with oral candidiasis, HPV lesions (papillo-
mas, focal epithelial hyperplasia or condyloma acumi-
natum) are more frequent when CD4 cell counts are 
lower;9 however, as opposed to oral candidiasis and 
pilous leukoplakia, HPV infection rates did not decrease 
following antiretroviral therapy.5,11 The most common 
type is type 32.17
Treatment has not been well defined; acid/caustic 
agents, cantharidin, topical podophyllin, topical cidofo-
vir, intralesional interferon-α, intralesional bleomycin, 
topical 5-fluoracil, or surgery (cryosurgery, CO
2
 laser, 
curettage, or cold blade excision) may be used.11
8. Periodontal disease: the main periodontal dise-
ases in HIV/AIDS patients are: linear gingival erythema, 
necrotizing ulcerative gingivitis, and necrotizing ulcera-
tive periodontitis. Linear gingival erythema presents as a 
band of intense vascular erythema around the gingival 
margin, accompanied by discomfort and gingival blee-
ding. Its frequency is 2 to 6% in developing countries.3
A few studies have suggested a relationship be-
tween gingival colonization by Candida species and 
periodontal disease in HIV patients, including linear 
gingival erythema. The most recent classification of 
the American Academy of Periodontology has placed 
linear gingival erythema within the category of gingival 
disease of fungal origin.5,18
Necrotizing ulcerative periodontitis may be di-
fferentiated from necrotizing ulcerative gingivitis by its 
rapid destruction of soft tissue and bone: teeth may be 
lost; there may be bleeding, intense pain, and halitosis. 
The treatment adds antibiotic therapy to the abovemen-
tioned measures for linear gingival erythema.5,11
9. Oral tuberculosis: this condition is rare; it 
affects 1.33% of seropositive patients (Miziara et al.19) 
There may be single or multiple superficial ulcers or 
papillomatous lesions usually on the palate and dorsum 
of the tongue; pain and bleeding may also be present. 
Oral lesions may be a manifestation of primary or se-
condary infection.19 A biopsy and culture are done for 
the diagnosis; the treatment is the same in patients with 
normal or compromised immune status.19
10. Lymphomas: the risk of an HIV-positive 
patient to develop non-Hodgkin’s lymphoma is 50 to 
200 times that of the general population. Up to 5% of 
seropositive patients develop this disease if antiretroviral 
therapy is not started;20 only Kaposi’s sarcoma is more 
frequent as an AIDS-associated tumor.
Seropositive users of injected drugs are especially 
at risk. The oral manifestations are present in the gin-
gival and alveolar processes, and may extend to the 
palate. The tonsils may also be involved.
The Epstein-Barr virus has been found in tissue 
samples; a biopsy is required for the diagnosis. Therapy 
consists of combined radiotherapy and chemotherapy.21 
The most common chemotherapy treatment is the CHOP 
protocol (cyclophosphamide, doxorubicin, vincristine, 
and prednisone).20
Nasosinusal manifestations
1. Rhinosinusitis: this disease is very common in 
seropositive patients – the prevalence ranges from 30 
% to 68 %.22 Paranasal sinuses are involved because 
of increased susceptibility to allergic rhinitis, decrea-
sed mucociliary clearance, and immune cell dysfunc-
tion.1,23,24 The microorganisms that cause acute infection 
in the general population are the same in HIV-infected 
patients; the treatment, therefore is similar.1,23 There is a 
higher incidence of Staphylococcus and Pseudomonas 
in these patients in both acute and chronic infections. 
Opportunistic bacteria should be taken into account if 
the disease progresses to immunosuppression, espe-
cially if the CD4 T lymphocyte count is below 200 cells.23
The clinical findings of acute infection are similar 
to those in non-HIV infected patients: headache, fever, 
purulent nasal discharge, nasal block, and posterior 
dripping. However, immunosuppressed patients are 
unable to mount an inflammatory response; thus, the 
clinical manifestations of sinus disease in these patients 
may be only chronic coughing, recurring lung infection, 
fever of unclear origin, or central nervous system infec-
tion.24 Miziara et al. found purulent rhinorrhea, nasal 
block, and headache as the most common complaints 
in patients with chronic rhinosinusitis.25
Imaging methods – computed tomography and 
magnetic resonance imaging are useful for the diagnosis 
or if there is complicated sinusitis.
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The medical treatment of acute and chronic cases 
is similar to that in non-HIV infected patients, consisting 
of antibiotics against Staphylococcus and Pseudomonas. 
The duration of therapy is still controversial; currently, 
three weeks are recommended for acute cases, and four 
to six weeks for chronic cases.1,23 Topical or systemic 
decongestants may be useful.23
Antibiotics based on cultures of sinusal content 
is used in patients that do not respond to therapy, or 
that present toxemia or with CD4 cell counts below 
50 cells/mm3 at the beginning of the disease. In non-
responding cases, complicated sinus disease, opportu-
nistic infection, or neoplasms should be sought as cases 
of treatment failure; imaging is useful in such cases.23
Endoscopic surgery may be beneficial in chronic 
or non-responding cases to reestablish sinus drainage 
and to support the diagnosis. There are still not enou-
gh published data to support surgery in seropositive 
patients.23
2. Allergic rhinitis: allergic conditions, including 
allergic rhinitis, develop or exacerbate twice as often 
in seropositive patients.23 It is thought to be a conse-
quence of B lymphocyte polyclonal activation, which 
increases the amount of immunoglobulins, especially 
Ig E. Increased Ig E levels cause the allergic symptoms 
in these patients.1,23
The clinical manifestations are similar to those in 
patients with normal immunity: thick rhinorrhea and 
nasal block. The treatment may be done with topical 
corticosteroids and antihistaminic drugs.1
Immunotherapy is a relevant tool for allergic rhi-
nitis patients that do not respond to the usual treatment; 
its use in seropositive patients, however, remains limi-
ted. Randhawa et al. reported a case of a seropositive 
patient aged 44 years, with non-responding allergic 
rhinitis, using ART, who was treated with immunothe-
rapy. These authors found that immunotherapy may 
have caused CD4 T cells to proliferate slightly and the 
viral load to increase; these findings disappeared with 
continuation of ART.26
3. Neoplasms: the most common neoplasms in 
seropositive patients are Kaposi’s sarcoma (KS) and lym-
phomas.24 KS may affect the mucosa in any part of the 
upper aerodigestive tract, including the nasopharynx. 
Lesions may present as plaques or nodules that appear 
similar to granulation tissue.24 Non-Hodgkin’s lympho-
ma may also develop in the nasal cavity, where it may 
cause nasal block, refractory chronic sinusitis, or other 
non-specific symptoms such as fever and weight loss.24
Imaging (computed tomography) is useful but 
cannot differentiate tumors from inflammation. Thus, 
biopsies are required for a diagnosis if warranted by 
the clinical examination.25
Manifestations in the neck
1. Enlarged lymph nodes in the neck: this is the 
most frequent finding in seropositive patients.1 The 
cause varies, ranging from infection to neoplasms; a 
reactive process is the most common finding.24 Prasad 
et al. found enlarged lymph nodes in the neck in 42% of 
seropositive patients with otorhinolaryngological mani-
festations of HIV infection.1 Generalized enlargement of 
neck lymph nodes may be found in over 70% of these 
patients within the first few months of seroconversion. It 
may be described as diffuse enlargement of neck lymph 
nodes involving two or more chains of extra-inguinal 
lymph nodes for over three months.1 Lymph nodes are 
symmetrical, soft, ranging in size from 1.0 to 5.0 cm, 
and located mostly in the posterior neck triangle.1,24 
Although this may be a benign process, fine needle 
aspiration biopsy may be needed.1 
- Presence of constitutional symptoms with no 
other associated manifestations;
- Asymmetric or non-generalized lymph node 
enlargement;
- Disproportional increase of a single lymph node 
in patients with generalized lymph node enlargement;
- Presence of peripheral cytopenia not explained 
by other factors.
The incidence of neck involvement by Mycobac-
terium tuberculosis has increased in seropositive pa-
tients.1 In subjects with advanced disease, 50% to 67% of 
tuberculous infection will manifest in extra-pulmonary 
sites, one of the main ones being the neck.24,27 Clinical 
findings may show only an enlarged and hardened 
neck.1 The PPD test and a chest radiograph are needed 
to confirm or exclude this infection.
Neoplasms, such as Kaposi’s sarcoma or LNH 
should be investigated if there is rapid increase in the 
neck volume and hardening of the neck. Histology may 
be needed in such cases.1 
2. Involvement of salivary glands: involvement of 
the parotids has been observed in 5% to 10% of HIV-
positive cases.28 This may occur because of benign or 
malign conditions in these patients. Parotid involvement 
may result in xerostomy, and progressive and painless 
enlargement of this gland.24 
Lymphoepithelial cysts are benign tumors that are 
highly specific for HIV infection; they probably result 
from secondary gland obstruction due to intra-parotid 
lymph node enlargement.24 These cysts are one of the 
initial manifestations of this infection, and are rarely 
found in patients with advanced disease.30 
Other conditions, such as lymphadenitis, chronic 
inflammation, or reactive intra-parotid lymph node en-
largement, may also cause hypertrophy of the glands.24 
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CT may show these cysts, which are almost 
always multiloculated. Fine needle aspiration is a safe 
diagnostic method; although this procedure may reduce 
the size of cysts, they tend to grow again, which is ex-
pected. Surgery is done if there is secondary infection 
or significant esthetic concerns.24,29 
In a few cases, CT and/or a physical examination 
may reveal a solid mass. The risk of malignancy incre-
ases markedly in these patients; the Kaposi sarcoma 
and lymphomas need to be investigated in these cases.1 
Steel et al. reported a rare case without a prior diagno-
sis of HIV in which there was chronic bilateral parotid 
involvement. Pathology of an intra-parotid lymph node 
revealed Kaposi’s sarcoma.30 
The diffuse infiltrative lymphocytic syndrome is a 
rare condition caused by infiltration of viscera by CD8 
T lymphocytes. Riviera et al. showed by immunohisto-
chemistry that the Epstein-Barr and the HIV viruses are 
involved in such cases.31 
It manifests as permanent CD8 T lymphocyte 
lymphocytosis, neck lymph node enlargement, and 
unilateral or bilateral parotid edema.32 The lungs are 
often involved, where the clinical presentation is simi-
lar to pneumonia due to Pneumocystis carinii. Other 
manifestations are: peripheral neuropathy, lymphocytic 
infiltration of the liver (hepatitis), myositis, and lym-
phocytic interstitial nephritis.33 A biopsy is essential to 
define the nature of parotid involvement,34 and treat-
ment is usually antiretroviral therapy.35 
Otologic manifestations
Otologic involvement due to the HIV is rare. 
However, AIDS because of the HIV includes a variety 
of clinical conditions that ENT specialists and clinicians 
should recognize.
Chandrasekhar et al found otologic manifestations 
in 33% of HIV patients in case series. Of these patients, 
34% had fullness of the ear, 32% had dizziness, 29% had 
hypoacusis, 26% had tinnitus, 23% had otalgia, and 5% 
had otorrhea. Otitis media was frequent.37 
Prasad et al monitored 968 HIV patients during 
8 years and encountered otologic involvement in 20% 
of them; chronic otitis media was the most common 
disease (13%).1
Clinical manifestations in the outer and middle 
ear in AIDS patients vary. They are generally caused 
by casual otologic infection and opportunistic diseases. 
The main diseases are: otitis externa, otomicosis, acute 
otitis media, recurring acute otitis media, secretory otitis 
media, chronic suppurative otitis media, and herpes 
zoster oticus. Opportunistic diseases in this context 
include: malignant otitis externa, chronic otitis media 
secondary to infection by Pneumocistis jiroveci, and 
neoplasms (Kaposi’s sarcoma).1,36,38,39 
1. Acute otitis externa: its incidence is not higher 
in AIDS patients compared to the general population.1 
It is typically caused by Pseudomonas aeruginosa, and 
less frequently by Aspergillus and Proteus. Excessive 
skin irritation and trauma are the main predisposing 
factors. The physical examination shows an edematous 
and erythematous outer ear canal, which may contain 
pus, resulting in conductive hypoacusis.24 The treatment 
consists of topical anti-pseudomonas ear drops and 
frequent cleaning of the outer ear canal.24 
2. Malignant otitis externa: Chandler described 
this disease in 1968; it consists of a necrotizing infection 
of the outer ear canal that may extend to the mastoid 
and petrous portion of the temporal bone, and cause 
cranial base osteomyelitis.36,40 Although this disease 
affects mostly elderly and diabetic individuals, immu-
nocompromised patients are also susceptible.36,41,42 
Pseudomonas aeruginosa is the causative agent in 
most cases.41,43 Reports of Proteus mirabilis and Asper-
gillus fumigates in HIV patients have been published.40 
Ress et al. (1990 and 1995) published a retrospective 
review of seven AIDS patients diagnosed with malignant 
otitis externa, of which two had positive cultures of 
outer ear canal secretions for Pseudomonas aeruginosa. 
The explanations were that patients were immunodefi-
cient, and had previously been given anti-pseudomonas 
drugs for community-acquired infection.43 
Pseudomonas aeruginosa infection is opportu-
nistic, and occurs rarely in healthy subjects. This gram-
negative bacteria is not normally found in the outer ear 
canal; it colonizes this area following minor trauma or 
excessive exposure to water.41 In seropositive patients, 
loss of immunity and the presence of other opportunistic 
infections (such as CMV), facilitate the development 
of malignant otitis externa with complications such as 
cranial base osteomyelitis.36,40,44 
The clinical manifestations are similar in seroposi-
tive AIDS patients and in healthy subjects.40 They consist 
of intense otalgia that does not respond to analgesics, 
and that becomes worse at night, temporal or mastoid 
headaches, and pain in the temporo-mandibular joint. 
Fever is uncommon. Otorrhea is found in most cases.40,41 
Granulation tissue in the outer ear canal is generally 
absent at otoscopy in these patients, which differs from 
seronegative subjects. The presence of this finding 
indicates immunity and a favorable prognosis.41,43 Cra-
nial nerve involvement may occur at any phase. Other 
complications are cerebral abscesses, meningitis, venous 
sinus thrombosis, and others.40,41 
The diagnosis is made based on clinical and 
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radiologic findings. Imaging should be done if malig-
nant otitis externa is suspected, preferably computed 
tomography of the temporal bones. This exam is useful 
in that it shows the extent of disease, helps define the 
response to therapy, and may indentify recurrences.40,43 
The treatment consists of anti-pseudomonas dru-
gs, such as ciprofloxacin and ceftazidime, for prolonged 
periods; these drugs considerably reduce the mortality in 
these patients.40,41 If the disease is caused by a fungus, 
the treatment consists of local cleaning and antifungal 
agents such as amphothericin B or itraconazol.41 
3. Otomicosis is a chronic and superficial disease 
of the outer ear canal; it is generally caused by Asper-
gillus niger.36 It may occur following use of antibiotics 
or during bacterial infection.45 The clinical findings 
are similar to those of bacterial otitis externa, but the 
diagnosis depends on identifying the fungus in the 
histopathological exam, as Aspergillus is almost always 
a saprophyte in the outer ear canal.36 The treatment 
consists of cleaning the outer ear canal and topical 
antifungal agents. If this treatment is ineffective, there 
may be invasive fungal infection of tissues. In this case, 
computed tomography or magnetic resonance imaging 
may be done to assess the extent of the disease.45 The 
treatment of invasive fungal infection consists of surgical 
debridement and systemic antifungal drugs.36,45 
4. Acute otitis media and recurring acute otitis 
media: studies of the temporal bones of seropositive 
patients have shown varied degrees of inflammation in 
the middle ear mucosa, even if there are no symptoms, 
which confirms otologic involvement by the virus.46,47 
Acute otitis media is a common infection in se-
ropositive and non-infected children,48 and may bring 
significant morbidity because of hearing loss.49 Miziara 
et al. monitored 459 immunocompromised HIV-infected 
Brazilian children and reported otitis media as the most 
common otorhinolaryngological manifestation.50 Barnett 
et al. found that by age 3 years, all HIV positive children 
will have had at least one episode of acute otitis media. 
Seronegative children have a 75% prevalence of acute 
otitis media at the same age.51 HIV infected children are 
more susceptible to acute otitis media than seropositive 
adults;52 Chandrasekhar et al. found that otitis media 
was present in 23% of these patients.37 
Recurring acute otitis media is defined as three or 
more episodes of acute otitis media within a 6-month 
period. These episodes are associated with the level of 
CD4 T lymphocytes, and are more common in immu-
nocompromised hosts.48,53 
Several studies have confirmed that the most 
common microorganisms involved in acute otitis me-
dia in seropositive non-immunocompromised children 
are similar to those in immunocompetent children, 
namely Streptococcus pneumonia and Haemophilus 
influenza.49,54 Immunocompromised children have a 
higher recurrence rate48 and Staphylooccus aureus as the 
possible causative agent.49 Acute otitis media secondary 
to mycobacterial infection – P. carinii, P. aeruginosa, 
and others – has been reported.
Clinical findings are similar to those in children 
without the virus. Immunosuppressed individuals have 
more severe disease and a higher complication rate, 
such as meningitis and bacteremia.55 The treatment 
given by otorhinolaryngologists is similar to that in im-
munocompetent patients – antibiotics against common 
germs. Tympanocentesis is done to collect material for 
analysis or to increase the coverage against S. aureus 
if therapy fails.49 
Zucotti et al have shown that episodes of recur-
ring acute otitis media may be reduced in 100% of chil-
dren given cefaclor for 6 months.53 The heptavalent anti-
pneumococcus vaccine was effective and immunogenic 
in HIV patients, but children with symptomatic virus 
infection were more susceptible to adverse reactions.56 
5. Secretory otitis media: otitis media with effu-
sion is related with Eustachian tube dysfunction, which 
generally is secondary to repeat otitis, atopia, or obs-
truction by nasopharyngeal factors (usually lymphoid 
hyperplasia).24,54,57 Thus, it is expected for seropositive 
children with recurring acute otitis media to be more 
susceptible to persisting middle ear effusion.58 
This is an important cause of conductive hearing 
loss, which may results in language development pro-
blems.54 Treating the predisposing factors resolves the 
symptoms in most cases.57 Myringotomy and grommet 
insertion may be necessary.54 
6. Suppurative chronic otitis media is a chronic 
inflammation of the middle ear and mastoid, associated 
with otorrhea and a perforated tympanic membrane. 
Bernaldez et al. have shown that the prevalence of 
this condition in seropositive children over a 10-year 
period was 13.24%, with a 3.31% annual incidence.59 
The most common microorganisms in this study were 
P. aeruginosa and Proteus. Therapy aims at eliminating 
the germs and improving patient immunity.59 Effective 
antiretroviral therapy reduces the prevalence of chronic 
otitis media in immunocompromised children, probably 
by increasing the number of CD4 T lymphocytes.50 
7. Pneumocistis jiroveci infection: P. jiroveci is 
probably the most common pathogen in HIV/AIDS pa-
tients.39 The main site for this agent is the lung, although 
extrapulmonary sites have been described, such as the 
temporal bone.57 
Extrapulmonary infection may occur through 
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several routes: hematogenic, lymphatic, contamination 
in the outer ear canal through the tympanic membrane, 
or retrograde dissemination through Eustachian’s tube. 
A likely hypothesis for P. jiroveci infection in this re-
gion is the similar embryological origin of the tympanic 
membrane and the pulmonary alveoli.60 
Clinical manifestations include otalgia and otor-
rhea; subcutaneous nodules or polyps in the outer ear 
canal may also be found. There may also be bilateral 
involvement, otitis media, and mastoiditis.36 Lung invol-
vement is not always concomitant.
This opportunistic infection should be suspec-
ted if a seropositive patient presents outer ear canal 
polyps and does not respond to the usual therapy. In 
such cases, the lesion should be biopsied to diagnose 
infection or a malignancy.61 The treatment consists of 
trimethoprim-sulfamethoxazole during three weeks.36 
8. Kaposi’s sarcoma: this is a progressive neo-
plasm that indicates AIDS.62 It may manifest as diffuse 
lesions in the ear or the tympanic membrane, or as 
exophytic lesions in the outer ear canal, leading to 
conductive hearing loss. Therapy ranges from surgical 
excision to chemo and radiotherapy.24 
9. Sensorineural hearing loss: its incidence in HIV 
patients ranges from 23% to 49%. A possible cause is 
primary HIV infection of the central nervous system 
or the auditory nerve.1 Other causes of sensorineural 
hearing loss should be sought, such as CNS infection, 
neoplasms, and ototoxic drugs.1,24 Most of these patients 
present worse sensorineural loss at high frequencies, 
but with close to normal speech discrimination. The-
rapy focuses on the specific cause, including hearing 
rehabilitation and aids.1 
10. Peripheral facial palsy: the presence of neuro-
logical findings is an important cause of morbidity and 
mortality in seropositive patients. Peripheral neuropathy 
comprises from 5% to 20% of neurological complica-
tions; peripheral facial palsy is rare.63,64 This condition 
may occur at any phase of HIV infection, although it 
is more common during the initial stages. Patients may 
present Bell’s palsy or the Guillain-Barré syndrome. In 
more advanced cases with clear immunosuppression, 
peripheral facial palsy is generally secondary to oppor-
tunistic infection of the CNS, such as neurotoxoplasmo-
sis or lymphoma.23 
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